Ben Scruggs, CEO of Altis Biosystems: Building the Gut Model That Predicts Which Drugs Actually Work
Ben Scruggs, CEO of Altis Biosystems, joins me to talk about building human gut models that help pharma, biotech, and nutrition companies predict how a drug or ingredient will actually behave in the body before it ever reaches a patient. The conversation covers what an epithelial barrier is and why the gut is such an overlooked bottleneck in drug development, how Altis's technology is being used for absorption studies, inflammation research, and toxicity screening, and why GLP-1 drugs make such a compelling test case for the company's platform.
Just as much of the episode is about Ben's own…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.